FMR LLC, an insider of Structure Therapeutics Inc (GPCR), sold 1,321 shares of the company on December 7, 2025, at a price of $61.05 per share, totaling approximately $81,000. Following this transaction, FMR LLC retains 1,321 shares of Structure Therapeutics.
Structure Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing oral therapeutics for chronic diseases with unmet medical needs. The company, which went public on February 3, 2023, has a market capitalization of $2.1 billion and an earnings per share (EPS) of -1.22. Its product pipeline includes Aleniglipron (GSBR-1290), ACCG-2671, and LTSE-2578, among others, targeting various conditions such as obesity and idiopathic pulmonary fibrosis.
Insider transactions, such as this sale, must be reported to the SEC, providing transparency into the actions of company executives. While individual sales can reflect personal financial planning motives, they should not be the sole basis for investment decisions. Evaluating patterns of insider activity across multiple insiders and time periods can offer more comprehensive insights into company sentiment.
Upcoming earnings reports for Structure Therapeutics are scheduled for May 6, 2026, and August 4, 2026, with EPS estimates of -0.41 and -0.43, respectively.